



An Application Data Sheet was filed in reference to this application on October 14, 2004.**10/511101**Page 1 of 2 Pages Original Substitute Supplemental Atty. Docket: KOGANTY4A

**COMBINED DECLARATION (37 CFR 1.63) AND POWER OF ATTORNEY FOR
UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET
(37 CFR 1.76)**

| | |
|---|---|
| TITLE OF THE INVENTION | SYNTHETIC GLYCO-LIPO-PEPTIDES AS VACCINES |
| <p>This declaration is directed to:</p> <p><input type="checkbox"/> the attached application;</p> <p><input type="checkbox"/> the application filed in the United States under 35 U.S.C. §111 on _____, as U.S. Appln. No. _____*: or</p> <p><input checked="" type="checkbox"/> the application which was/will be filed in the U.S. under 35 U.S.C. §371 by entry into the U.S. national stage of an international (PCT) application, PCT/US03/10750 filed April 9, 2003, entry requested on October 14, 2004*: national stage application received U.S. Appln. No.10/511,101*; §371/§102(e) date October 14, 2004* (* if known)</p> <p><input type="checkbox"/> as amended on _____ (if applicable).</p> | |
| <p>I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;</p> <p>I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;</p> <p>I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.</p> <p>All statements made herein of my/owa knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.</p> <p>As a named inventor, I hereby appoint the following registered practitioners to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:</p> <p style="text-align: center;">All of the practitioners associated with Customer Number 001444</p> <p>Direct all correspondence to the address associated with Customer Number 001444, which is presently:</p> <p style="text-align: center;">BROWDY AND NEIMARK, P.L.L.C. 624 Ninth Street, N.W. Washington, D.C. 20001-5303 (202) 628-5197</p> <p>The undersigned hereby authorizes the U.S. Attorneys or Agents appointed herein to accept and follow instructions from <u>HOIBERG</u> as to any action to be taken in the U.S. Patent and Trademark Office regarding this application without direct communication between the U.S. Attorneys or Agents and the undersigned. In the event of a change of the persons from whom instructions may be taken, the U.S. Attorneys or Agents appointed herein will be so notified by the undersigned.</p> <p>FULL NAME OF INVENTOR(S)</p> <p>Inventor one: <u>R. Rao KOGANTY</u></p> <p>Signature:  Citizen of: <u>Canada</u></p> <p>Inventor two: <u>Zi-Hua JIANG</u></p> <p>Signature:  Citizen of: <u>Canada</u></p> | |

BEST AVAILABLE COPY

Page 2 of 2 Pages

Atty. Docket: KOGANTY4A

Title: SYNTHETIC GLYCO-LIPO-PEPTIDES AS VACCINESU.S. Application filed _____ Serial No. 10/511,101PCT Application filed April 9, 2003 Serial No. PCT/US03/10750Inventor three: Damayanthi YALAMATISignature: Damayanthi Citizen of: CanadaInventor four: Sham GANDHISignature: Sham Gandhi Citizen of: CanadaInventor five: Wladyslaw BUDZYNSKISignature: _____ Citizen of: Poland and CanadaInventor six: Mark KRANTZSignature: Mark J. Krantz Citizen of: United StatesInventor seven: B. Michael LONGENECKERSignature: /s/ Citizen of: United States and Canada Additional inventors or a legal representative are being named on _____ additional form(s) attached hereto.

All inventors must review application and declaration before signing. All alterations must be initialed and dated by all inventors prior to execution. No alterations can be made after the declaration is signed. All pages of the declaration must be seen by all inventors.

Resolving conflicts between Application Data Sheets and Declaration occurs as follows: (1) normally, the latest submitted information governs, (2) if an Application Data Sheet and a declaration are filed the same day, the Application Data Sheet governs, except with respect to the naming of inventors and the identification of their citizenship. See 37 CFR 1.76(d).

Rec'd PCT/PTO 12 SEP 2005

An Application Data Sheet was filed in reference to this application on October 14, 2004.

Page 1 of 2 Pages [X] Original [] Substitute [] Supplemental Atty. Docket: KOGANTY4A

10/511101

**COMBINED DECLARATION (37 CFR 1.63) AND POWER OF ATTORNEY FOR
UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET
(37 CFR 1.76)**

| | |
|---|---|
| TITLE OF THE INVENTION | SYNTHETIC GLYCO-LIPO-PEPTIDES AS VACCINES |
| <p>This declaration is directed to:</p> <p>[] the original application;</p> <p>[] the application filed in the United States under 35 U.S.C. §111 on _____, as U.S. Appln. No. _____; or</p> <p>[X] the application which was/will be filed in the U.S. under 35 U.S.C. §371 by entry into the U.S. national stage of an International (PCT) application, PCT/US03/10750 filed April 9, 2003, entry requested on October 14, 2004*; national stage application received U.S. Appln. No.10/511,101*; §371/§102(c) date October 14, 2004* (* if known)</p> <p>[] as amended on _____ (if applicable).</p> <p>I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;</p> <p>I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;</p> <p>I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.</p> <p>All statements made herein of my/our knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.</p> <p>As a named inventor, I hereby appoint the following registered practitioners to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:</p> <p style="text-align: center;">All of the practitioners associated with Customer Number 001444</p> <p>Direct all correspondence to the address associated with Customer Number 001444, which is presently:</p> <p style="text-align: center;">BROWDY AND NEIMARK, P.L.L.C. 624 Ninth Street, N.W. Washington, D.C. 20001-5303 (202) 628-5197</p> <p>The undersigned hereby authorizes the U.S. Attorneys or Agents appointed herein to accept and follow instructions from <u>HOIBERG</u> as to any action to be taken in the U.S. Patent and Trademark Office regarding this application without direct communication between the U.S. Attorneys or Agents and the undersigned. In the event of a change of the persons from whom instructions may be taken, the U.S. Attorneys or Agents appointed herein will be so notified by the undersigned.</p> <p>FULL NAME OF INVENTOR(S)</p> <p>Inventor one: <u>R. Rao KOGANTY</u></p> <p>Signature: <u>[Signature]</u> Citizen of: <u>Canada</u></p> <p>Inventor two: <u>ZI-HUA JIANG</u></p> <p>Signature: <u>[Signature]</u> Citizen of: <u>Canada</u></p> | |

Page 2 of 2 Pages

Title: SYNTHETIC GLYCO-LIPO-PEPTIDES AS VACCINES

U.S. Application filed


Serial No. 10/311,101

PCT Application filed April 9, 2003

Serial No. PCT/US03/10740

Att'y. Docket KOGANTY4A

Inventor three: Damayanthi YALAMATI

Signature: 

Citizen of Canada

Inventor four: Sham GANDHI

Signature: 

Citizen of Canada

Inventor five: Wladyslaw BUDZYNSKI

Signature: 

Citizen of Poland and Canada

Inventor six: Mark KRANTZ

Signature:

Citizen of United States

Inventor seven: B. Michael ONGENECKER

Signature:

Citizen of United States and Canada

 Additional inventors or a legal representative are being named on _____ additional form(s) attached hereto.



All inventors must review application and declaration before signing. All alterations must be initialed and dated by all inventors prior to execution. No alterations can be made after the declaration is signed. All pages of the declaration must be signed by all inventors.

Resolving conflicts between Application Data Sheets and Declaration occurs as follows: (1) normally, the latest submitted information governs, (2) if an Application Data Sheet and a declaration are filed the same day, the Application Data Sheet governs, except with respect to the naming of inventors and the identification of their citizenship. See 37 CFR 1.76(d).

0051110

An Application Data Sheet was filed in reference to this application on October 14, 2004.Page 1 of 2 Pages Original Substitute Supplemental Atty. Dealer: KOGANTY4A

**COMBINED DECLARATION (37 CFR 1.63) AND POWER OF ATTORNEY FOR
UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET
(37 CFR 1.76)**

| | |
|---|---|
| TITLE OF THE INVENTION | SYNTHETIC GLYCOPOLYPEPTIDES AS VACCINES |
| <p>This declaration is directed to:</p> <p><input type="checkbox"/> the attached application;</p> <p><input type="checkbox"/> the application filed in the United States under 35 U.S.C. §111 on _____, 63 U.S. Appl. No. _____; or</p> <p><input checked="" type="checkbox"/> the application which was/will be filed in the U.S. under 35 U.S.C. §371 by entry into the U.S. national stage of an international (PCT) application, PCT/US03/10750 filed April 9, 2003, entry requested on October 14, 2004; national stage application received U.S. Appln. No. 10/311,101; §371/§102(e) date October 14, 2004 (* if known)</p> <p><input type="checkbox"/> as amended on _____ (if applicable).</p> <p>I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;</p> <p>I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;</p> <p>I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.</p> <p>All statements made herein of my/our knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.</p> <p>As a named inventor, I hereby appoint the following registered practitioners to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:</p> <p align="center">All of the practitioners associated with Customer Number 001444</p> <p>Direct all correspondence to the address associated with Customer Number 001444, which is presently:</p> <p align="center">HROWDY AND NEIMARK, P.J.L.C. 624 Ninth Street, N.W. Washington, D.C. 20001-5303 (202) 628-5197</p> <p>The undersigned hereby authorizes the U.S. Attorneys or Agents appointed herein to accept and follow instructions from <u>HOIBERG</u> as to any action to be taken in the U.S. Patent and Trademark Office regarding this application without direct communication between the U.S. Attorneys or Agents and the undersigned. In the event of a change of the persons from whom instructions may be taken, the U.S. Attorneys or Agents appointed herein will be so notified by the undersigned.</p> | |
| <p>FULL NAME OF INVENTOR(S)</p> <p>Inventor one: <u>R. Rao KOGANTY</u></p> <p>Signature: </p> <p>Citizen of: Canada</p> <p>Inventor two: <u>Zi-Hua JIANG</u></p> <p>Signature: </p> <p>Citizen of: Canada</p> | |

Page 2 of 2 Pages

Atty. Docket: KOGANTY4A

Title: SYNTHETIC GLYCO-LIPO-PEPTIDES AS VACCINESU.S. Application filed _____ Serial No. 10/511,101PCT Application filed April 9, 2003 Serial No. PCT/US03/10730Inventor three: Damayanthi YALAMAIISignature: Damayanthi Citizen of: CanadaInventor four: Shan GANDHISignature: Shan Gandhi Citizen of: CanadaInventor five: Wladyslaw BIUDZYNSKISignature: _____ Citizen of: Poland and CanadaInventor six: Mark KRANTZSignature: _____ Citizen of: United StatesInventor seven: B. Michael LONGENECKERSignature: B. Michael LONGENECKER Citizen of: United States and Canada Additional inventors or a legal representative are being named on _____ additional form(s) attached hereto.

All inventors must review application and declaration before signing. All alterations must be initialed and dated by all inventors prior to execution. No alterations can be made after the declaration is signed. All pages of the declaration must be seen by all inventors.

Resolving conflicts between Application Data Sheets and Declaration occurs as follows: (1) normally, the latest submitted information governs, (2) if an Application Data Sheet and a declaration are filed the same day, the Application Data Sheet governs, except with respect to the naming of inventors and the identification of their citizenship. See 37 CFR 1.76(d).

BEST AVAILABLE COPY